Tahoe Therapeutics’ cover photo
Tahoe Therapeutics

Tahoe Therapeutics

Biotechnology Research

Mapping how chemistry perturbs biology to build a virtual model of the human cell. Formerly known as Vevo Therapeutics.

About us

Tahoe Therapeutics (formerly Vevo Therapeutics) is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Tahoe is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in South San Francisco, CA, Tahoe was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Learn more at www.tahoebio.ai.

Website
https://www.tahoebio.ai/
Industry
Biotechnology Research
Company size
11-50 employees
Type
Privately Held
Founded
2022

Employees at Tahoe Therapeutics

Updates

  • Tahoe Therapeutics reposted this

    If you want to know more about the broader context of Tahoe-x1, read the great story by Andrew Dunn on Endpoints News. https://lnkd.in/g5Em_Z7H

    Today we’re introducing Tahoe-x1 (Tx1), a 3 billion parameter single-cell foundation model that learns unified representations of genes, cells, and drugs, open-sourced on Hugging Face.   The same 15-person team (10 until a couple of weeks ago) that built the Tahoe-100M dataset to address the data challenge in scaling AI models in cell biology, has now built Tx1, the largest and first compute-efficient model at this scale trained on perturbation-rich data. And true to the original spirit, we are releasing it open source with open weights (see comments).  Built on our Tahoe-100M dataset, Tx1 is over 10× more efficient to train than most other cell-state models. We’re releasing Tx1 together with new benchmarks we designed to assess performance in cancer-relevant and drug-discovery tasks, where Tx1 achieves state-of-the-art results. Tx1 makes it possible, for the first time, to systematically search for better architectures at the billion-parameter scale and explore whether the scaling laws that transformed language and protein modeling can now do the same for cell biology.

  • If you want to know more about the broader context of Tahoe-x1, read the great story by Andrew Dunn on Endpoints News. https://lnkd.in/g5Em_Z7H

    Today we’re introducing Tahoe-x1 (Tx1), a 3 billion parameter single-cell foundation model that learns unified representations of genes, cells, and drugs, open-sourced on Hugging Face.   The same 15-person team (10 until a couple of weeks ago) that built the Tahoe-100M dataset to address the data challenge in scaling AI models in cell biology, has now built Tx1, the largest and first compute-efficient model at this scale trained on perturbation-rich data. And true to the original spirit, we are releasing it open source with open weights (see comments).  Built on our Tahoe-100M dataset, Tx1 is over 10× more efficient to train than most other cell-state models. We’re releasing Tx1 together with new benchmarks we designed to assess performance in cancer-relevant and drug-discovery tasks, where Tx1 achieves state-of-the-art results. Tx1 makes it possible, for the first time, to systematically search for better architectures at the billion-parameter scale and explore whether the scaling laws that transformed language and protein modeling can now do the same for cell biology.

  • Tahoe Therapeutics reposted this

    Today we’re introducing Tahoe-x1 (Tx1), a 3 billion parameter single-cell foundation model that learns unified representations of genes, cells, and drugs, open-sourced on Hugging Face.   The same 15-person team (10 until a couple of weeks ago) that built the Tahoe-100M dataset to address the data challenge in scaling AI models in cell biology, has now built Tx1, the largest and first compute-efficient model at this scale trained on perturbation-rich data. And true to the original spirit, we are releasing it open source with open weights (see comments).  Built on our Tahoe-100M dataset, Tx1 is over 10× more efficient to train than most other cell-state models. We’re releasing Tx1 together with new benchmarks we designed to assess performance in cancer-relevant and drug-discovery tasks, where Tx1 achieves state-of-the-art results. Tx1 makes it possible, for the first time, to systematically search for better architectures at the billion-parameter scale and explore whether the scaling laws that transformed language and protein modeling can now do the same for cell biology.

  • Tahoe Therapeutics reposted this

    View profile for Andrew Dunn
    Andrew Dunn Andrew Dunn is an Influencer

    Senior Biopharma Correspondent at Endpoints News

    EXCLUSIVE: Tahoe Therapeutics, a 15-employee South San Francisco biotech, has developed the largest virtual cell model to date. And it's giving it away for free. I talked with CEO Nima Alidoust, CSO Johnny Yu, and ML director Shreshth Gandhi about why they plan to open-source Tahoe-x1 tomorrow, and what's next for virtual cell models and for Tahoe. The biotech raised a $30 million Series A earlier this year at a valuation and already is eyeing the clinic. Alidoust told me they are "getting very close to putting together an IND package for our lead program." More here in my latest exclusive for Endpoints News: https://lnkd.in/emDrAaNg

  • We are excited to share Tahoe-x1 with the world tomorrow! And thanks Andrew Dunn for the coverage.

    We at Tahoe Therapeutics believe models that live up to the title "virtual cell" are a few years away. To build them, we need data. And we need open source, compute-efficient models that make the search for the ultimate models an empirical problem. Our Tahoe-100M dataset was a step towards solving the data challenge. Tomorrow, we will open source Tahoe-x1, a 3B parameter single-cell foundation model, as a step towards solving the modeling challenge. In anticipation of that, we had a chat with Andrew Dunn from Endpoints News. Enjoy!

    • No alternative text description for this image
  • Tahoe Therapeutics reposted this

    We at Tahoe Therapeutics believe models that live up to the title "virtual cell" are a few years away. To build them, we need data. And we need open source, compute-efficient models that make the search for the ultimate models an empirical problem. Our Tahoe-100M dataset was a step towards solving the data challenge. Tomorrow, we will open source Tahoe-x1, a 3B parameter single-cell foundation model, as a step towards solving the modeling challenge. In anticipation of that, we had a chat with Andrew Dunn from Endpoints News. Enjoy!

    • No alternative text description for this image
  • Tahoe Therapeutics reposted this

    🧬 Tahoe Workshop at scverse conference 2025 🧬 Disease Biology and Therapeutics in the Age of Frontier Datasets How are large-scale perturbation datasets transforming research in disease biology and drug discovery? This session will focus on how large-scale perturbation datasets are enabling new capabilities in disease biology and translational science — moving from static maps to predictive models and controllable systems. 📅 November 17-19, 2025 at Stanford University, California 🏛️ Format: 2 days of main conference + 1 day of satellite workshops across the Bay Area ℹ️ More info: https://lnkd.in/dPc6sMHf 🚀 Ready to join us? Register: https://lnkd.in/dTRydMwj Tahoe Therapeutics #scverse2025 #ComputationalBiology #DrugDiscovery #TahoeTherapeutics #SingleCell #PerturbationBiology

    • No alternative text description for this image
  • Tahoe Therapeutics reposted this

    View profile for Johnny Yu

    CSO and Cofounder at Tahoe Therapeutics (formerly Vevo)

    🌟 Come see what we’re building at Tahoe Therapeutics at #ASHG25! 🌟 We’re proud to share that Airol Anne U., co-first author on our Tahoe-100M paper and a true builder 🔨 on the Mosaic platform, will be presenting our latest work — including unpublished data that pushes the boundaries of single-cell discovery. Airol has been instrumental in making this project a reality. Her creativity, technical rigor, and perseverance embody what makes Tahoe so special. 💪 📍 Today at 2:30 PM — Board 4101F Come by to meet Airol, learn more about our next generation of large-scale single-cell datasets, and see what’s coming next from Tahoe Therapeutics. 🧬 #ASHG25 #singlecell #genomics #Mosaic #Tahoe100M #TeamTahoe

    • No alternative text description for this image
  • Tahoe Therapeutics reposted this

    What if we combined genetic & chemical perturbations to infer previously unknown mechanisms of action for any given compound? Compound perturbations in Tahoe-100M aligned with CRISPR data allowed us to do that at scale. In our new blog post, we share an example of how powerful this combination can be. We paired Tahoe-100M with Myllia’s CROP‑seq: 218 CRISPR targets in A549. We unify drug & gene maps via gene‑set scoring (MSigDB, Vision), enabling direct comparison of drug‑ vs gene‑induced signatures. The paradigm shift: treat drugs as programmable phenotypic levers—design compounds to recreate desired transcriptional states. This blueprint—uniting CRISPR genetics with small‑molecule perturbations—fuels our upcoming 1B+ cell atlas: more cells, more contexts, greater confidence in mechanism & phenocopy. Read more in the full post about how we used it to recapitulate target pathways of compounds with known MoA, uncovered new MoAs for other compounds, and how the method generally performs. Link in comments.

    • No alternative text description for this image
  • Tahoe Therapeutics reposted this

    Join us on September 4th at MBC BioLabs San Francisco for our next Founders at Work Speaker Series: Tahoe Therapeutics on “Building Frontier Datasets to Power the Virtual Cell,” featuring Johnny Yu, CSO & Co-founder. Generation of large scale single-cell datasets are now integral to the vision of the Virtual cell. Tahoe Therapeutics is leading a generation of frontier scale datasets across diverse perturbations to i) develop programs from unbiased datasets ii) enable modeling of the cell states. Please register here to save your spot ➡️ https://lu.ma/wkx2xh3g

Similar pages

Browse jobs

Funding